AWA
SNDX icon

Arkadios Wealth Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Arkadios Wealth Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-510
Closed -$9K – 1595
2021
Q3 		$9K Hold
510
– – ﹤0.01% 1474
2021
Q2 		$8K Hold
510
– – ﹤0.01% 1607
2021
Q1 		$11K Hold
510
– – ﹤0.01% 1170
2020
Q4 		$11K Hold
510
– – ﹤0.01% 937
2020
Q3 		$8.98K Sell
510
-1,190
-70% -$18.1K ﹤0.01% 766
2020
Q2 		$24.6K Buy
+1,700
New +$25.9K 0.01% 501

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arkadios Wealth Advisors's SNDX Position: Q4 2021 in Review

Arkadios Wealth Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2021, closing a stake of 510 shares — an estimated $9K sold.

Arkadios Wealth Advisors first reported a position in SNDX in Q2 2020 and held it in 6 quarters. The position peaked at $24.6K in Q2 2020. 132 funds tracked by Wall St. Rank hold SNDX as of Q4 2021.

  • Arkadios Wealth Advisors reported no remaining Syndax Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 510 Syndax Pharmaceuticals shares in Q4 2021, an estimated $9K.
  • Arkadios Wealth Advisors first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 6 quarters.
  • Arkadios Wealth Advisors's Syndax Pharmaceuticals position peaked at $24.6K in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.